arGEN-X BV (ARGX) versus Its Peers Financial Review

arGEN-X BV (NASDAQ: ARGX) is one of 92 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare arGEN-X BV to similar companies based on the strength of its dividends, risk, earnings, valuation, profitability, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

52.8% of arGEN-X BV shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 17.1% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.


This table compares arGEN-X BV and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
arGEN-X BV Competitors -6,095.52% -68.88% -26.12%

Earnings and Valuation

This table compares arGEN-X BV and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
arGEN-X BV $44.74 million -$31.73 million -70.13
arGEN-X BV Competitors $1.03 billion $94.79 million -1.79

arGEN-X BV’s competitors have higher revenue and earnings than arGEN-X BV. arGEN-X BV is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings for arGEN-X BV and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
arGEN-X BV 0 0 5 0 3.00
arGEN-X BV Competitors 509 1807 4712 170 2.63

arGEN-X BV currently has a consensus target price of $108.50, suggesting a potential upside of 10.51%. As a group, “Biological products, except diagnostic” companies have a potential upside of 16.28%. Given arGEN-X BV’s competitors higher possible upside, analysts plainly believe arGEN-X BV has less favorable growth aspects than its competitors.

About arGEN-X BV

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. It is also developing ARGX-111 to treat solid tumors; ARGX-109 for the treatment of rheumatoid arthritis; ARGX-112 to treat skin inflammation; ARGX-115, a cancer immunotherapy-focused product candidate; and ARGX-116 for the treatment of dyslipidemia. The company has license and collaboration agreements with AbbVie S.Á.R.L.; Bird Rock Bio, Inc.; LEO Pharma A/S; Staten Biotechnology B.V.; and Shire International GmbH. argenx SE was founded in 2008 and is based in Breda, the Netherlands.

Receive News & Ratings for arGEN-X BV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for arGEN-X BV and related companies with's FREE daily email newsletter.

Leave a Reply